Recombinant Human Growth Hormone Trial Evaluates Efficacy, Safety for Idiopathic Short Stature in Korea

Approximately 70-80% of children presenting with short stature have idiopathic short stature (ISS), a diagnosis of exclusion without an identifiable cause, which can significantly impact psychosocial well-being. Recombinant human growth hormone (hGH) is a primary therapeutic option, stimulating linear growth by binding to the GH receptor and promoting IGF-1 production. However, individual responses to hGH vary, highlighting the need for robust efficacy and safety data in specific populations. This trial aims to provide crucial evidence for hGH use in the Korean population with ISS, supporting individualized treatment strategies.

This Phase 3 clinical trial was conducted in Korea to assess recombinant human growth hormone (hGH) in subjects diagnosed with idiopathic short stature. The study's primary objective was to evaluate both the efficacy, specifically focusing on height velocity, and the overall safety profile of hGH treatment. While the abstract does not provide specific details regarding the exact dosage, frequency, duration of treatment, or the total number of participants, typical hGH trials for ISS often involve daily subcutaneous injections administered over several years, often compared against a placebo or untreated control group.

The provided abstract outlines the aim of this Phase 3 trial, which is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in children with idiopathic short stature in Korea. However, specific quantitative results, such as improvements in height velocity, changes in height standard deviation scores (SDS), or detailed adverse event rates, are not presented in this summary. The trial's overarching goal is to determine if hGH can significantly enhance growth parameters and maintain an acceptable safety profile within this specific patient population, thereby informing clinical guidelines for its use.